Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. BJS 2018; 105: 1480-1486.
Published: 12th June 2018
Authors: B.‐H. Min, M. Hong, J. H. Lee, P.‐L. Rhee, T. S. Sohn, S. Kim et al.
With the widespread use of endoscopy, small and low‐grade type 3 gastric neuroendocrine tumours (NETs) are increasingly being detected. The clinicopathological features, biological behaviour and appropriate treatment strategy for these NETs remain unclear.
Patients with biopsy‐proven gastric NET and a normal fasting serum gastrin level were identified from a prospectively maintained database. Clinicopathological features and long‐term outcome of local resection for type 3 NETs were reviewed retrospectively and compared according to tumour grade.
Some 32 patients with type 3 gastric NETs were included (25 patients with NET grade G1, 5 with G2 and 2 with G3). Pathological tumour size was 2·0 cm or less in 30 patients. All tumours were well differentiated, even G3 lesions, and all tumours but one were confined to the submucosal layer. G1 NETs were significantly smaller and had a significantly lower lymphovascular invasion rate than G2 and G3 NETs. Twenty‐two patients with a G1 NET without lymphovascular invasion were treated with wedge or endoscopic resection. After a median follow‐up of 59 (range 6–102) months, no patient with a G1 NET of 1·5 cm or smaller developed recurrence and one patient with a G1 NET larger than 1·5 cm had recurrence in a perigastric lymph node. Among seven patients with a G2 or G3 NET, two had lymph node metastasis and one had liver metastases.
Low‐grade type 3 gastric NET has non‐aggressive features and a favourable prognosis. Wedge or endoscopic resection may be a valid option for patients with type 3 gastric G1 NET no larger than 1·5 cm without lymphovascular invasion.Full text
You may also be interested in
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Authors: T. Hølmebakk, B. Bjerkehagen, I. Hompland, S. Stoldt, K. Boye
Notes: Tumour rupture is most important
Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
Authors: B.‐Y. Wang, S.‐C. Wu, H.‐C. Chen, W.‐H. Hung, C.‐H. Lin, C.‐L. Huang et al.
Notes: Surgery after chemoradiation indicated
Effect of preoperative biliary drainage on cholestasis‐associated inflammatory and fibrotic gene signatures in perihilar cholangiocarcinoma. BJS 2019; 106: 55-58.
Authors: M. J. Reiniers, L. de Haan, R. Weijer, J. K. Wiggers, A. Jongejan, P. D. Moerland et al.
Impact of postoperative complications on outcomes after oesophagectomy for cancer. BJS 2019; 106: 111-119.
Authors: L. Goense, J. Meziani, J. P. Ruurda, R. van Hillegersberg
Meta‐analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes.
Authors: M. Roman, A. Monaghan, G. F. Serraino, D. Miller, S. Pathak, F. Lai et al.
Notes: Possible but how much is enough?
Multicentre cohort study of antihypertensive and lipid‐lowering therapy cessation after bariatric surgery.
Authors: J. Thereaux, T. Lesuffleur, S. Czernichow, A. Basdevant, S. Msika, D. Nocca et al.
Notes: Better than controls
Overall survival before and after centralization of gastric cancer surgery in the Netherlands. BJS 2018; 105: 1807-1815.
Authors: M. van Putten, S. D. Nelen, V. E. P. P. Lemmens, J. H. M. B. Stoot, H. H. Hartgrink, S. S. Gisbertz et al.
Notes: Practice makes perfect?
Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus. BJS 2018; 105: 1793-1798.
Authors: S. Mine, M. Watanabe, K. Kumagai, A. Okamura, K. Yamashita, M. Hayami et al.
Notes: Extended dissection not needed
Population‐based cohort study of diabetes mellitus and mortality in gastric adenocarcinoma. BJS 2018; 105: 1799-1806.
Authors: J. Zheng, S.‐H. Xie, G. Santoni, J. Lagergren
Notes: Diabetes increases risk
Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. BJS 2018; 105: 1639-1649.
Authors: A. R. Davies, D. Myoteri, J. Zylstra, C. R. Baker, W. Wulaningsih, M. Van Hemelrijck et al.
Notes: Nodal response predicts survival
Authors: H. Mackenzie, S. R. Markar, A. Askari, O. Faiz, M. Hull, S. Purkayastha et al.
Network meta‐analysis of surgical management of gastro‐oesophageal reflux disease in adults. BJS 2018; 105: 1398-1407.
Authors: M. A. Amer, M. D. Smith, C. H. Khoo, G. P. Herbison, J. L. McCall